Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Napo Pharmaceuticals has terminated its collaboration agreement with Salix Pharmaceuticals, which covered commercial development of the drug compound, crofelemer.
Subscribe to our email newsletter
The compound is used as a treatment for diarrhea, a life-threatening ailment that impacts millions of people across the world.
The termination has been done as Salix is said to have breached the Collaboration Agreement.
Following the termination of the collaboration agreement, Napo is likely to pursue an NDA, enter into new licensing agreements and seek commercialization plans for crofelemer.